Total Company Value: Calliditas Therapeutics AB (CALT)

Calliditas Therapeutics (CALT) is implementing strict laboratory safety standards and transitioning to biodegradable packaging to protect the environment. The business relies on stable demand for kidney therapy, which ensures crisis resilience and an absence of seasonality. Calliditas Therapeutics (CALT) is deploying software robots for clinical data analysis and automating molecule screening. The current enterprise value is . The market price action for this metric is presented below.

For the long-term investor, the reliability of Calliditas Therapeutics (CALT) is determined by the enterprise value, which sums the market capitalization and liabilities while subtracting cash to determine the actual buyout price of the business. The growth of this metric reflects the expansion of the company's fundamental value amid an active market capture of IgA nephropathy therapy in the US and Europe.